Projects
 

Oral GLP-1 Analogue

Primary Indication Treatment of Type 2 diabetes mellitus
Stage of Development Preclinical
  • Outlicensing opportunity - providing oral formulation technology to GLP-1 analogue
  • Stimulates insulin formation and release when blood glucose levels are high
  • Reduces glucose output from the liver
  • Improves insulin sensitivity and the function of ß-cells
  • Slows emptying of stomach and reduces desire to eat